CytomX Therapeutics (NASDAQ:CTMX) Upgraded to “Overweight” at JPMorgan Chase & Co.

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a report released on Monday, Marketbeat reports. The brokerage presently has a $12.00 target price on the biotechnology company’s stock, up from their previous target price of $7.00. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 56.27% from the stock’s current price.

Other analysts have also issued research reports about the company. Guggenheim reiterated a “buy” rating and issued a $10.00 price target on shares of CytomX Therapeutics in a report on Monday, March 9th. Piper Sandler upped their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Barclays increased their target price on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Finally, Cantor Fitzgerald boosted their price objective on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.38.

CytomX Therapeutics Price Performance

Shares of NASDAQ:CTMX traded up $3.00 on Monday, hitting $7.68. 85,620,283 shares of the company’s stock were exchanged, compared to its average volume of 4,775,381. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of 19.34 and a beta of 2.44. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $8.21. The business’s 50 day simple moving average is $5.19 and its two-hundred day simple moving average is $4.04.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CTMX. Precision Wealth Strategies LLC acquired a new stake in CytomX Therapeutics during the 3rd quarter worth about $756,000. Baker BROS. Advisors LP raised its stake in shares of CytomX Therapeutics by 22.0% in the third quarter. Baker BROS. Advisors LP now owns 4,250,826 shares of the biotechnology company’s stock worth $13,560,000 after purchasing an additional 766,600 shares during the last quarter. Inspire Investing LLC acquired a new stake in shares of CytomX Therapeutics during the third quarter worth about $1,667,000. Vivo Capital LLC purchased a new stake in CytomX Therapeutics in the second quarter valued at approximately $13,096,000. Finally, Franklin Resources Inc. acquired a new stake in CytomX Therapeutics during the 2nd quarter valued at approximately $13,096,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

Key Stories Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 dose-expansion data for varsetatug masetecan showed confirmed response rates of 32% (10 mg/kg Q3W) and 20% (8.6 mg/kg Q3W) with estimated PFS ~7 months and manageable grade 3 diarrhea (~10%); company is targeting mid-year FDA interactions to discuss a potential registrational trial and has initiated combination studies — this clinical readout is the primary catalyst for the stock move. CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
• Neutral Sentiment: Company published its 2025 financial results and a business update and hosted a conference call/slide deck providing context on the program timelines and cash/operating outlook — useful for judging runway and development timing. CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst previews and coverage highlighted the Q4 print and the clinical readout as the key near-term drivers; keep an eye on any updated analyst notes or revised models following the results. CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
• Negative Sentiment: Q4 results disappointed: GAAP loss of $0.22/sh vs. Zacks consensus loss of $0.08, and revenue of $0.66M missed expectations (~$7.33M). The financial miss raises near-term uncertainty around commercial/partner revenues and will push focus to cash burn and financing needs. CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.